Revenue growth of 99% YoY with accelerating consumable pull-through and margin expansion signals strong product-market fit. The $197.8M IPO cash removes near-term funding risk. Watch for Q2 guidance in August — if revenue trajectory sustains >80% YoY growth, the stock could re-rate higher. No consensus estimates available for surprise calculation.
Price Chart
Executive Summary
Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consumable growth and 78% instrument growth. Net loss widened to $21.3M from $7.7M due to $8.6M convertible note remeasurement loss and higher operating expenses. The company completed a $197.8M net IPO in April 2026 and will not provide full-year guidance until Q2 earnings.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $26.0M, +99% YoY vs $13.1M
- Consumable revenue $14.0M, +178% YoY; instrument revenue $7.4M, +78% YoY
- Gross margin expanded to 56% from 49% YoY on manufacturing efficiencies and product mix
- Net loss $21.3M vs $7.7M, including $8.6M non-cash convertible note remeasurement loss
- Completed IPO in April 2026, raising $197.8M net proceeds; cash + restricted cash $69.5M at quarter end
- Full-year 2026 revenue guidance deferred to Q2 earnings in August 2026
Financial Impact
Revenue doubled YoY to $26.0M; gross margin up 700bps to 56%; net loss widened by $13.6M primarily due to $8.6M non-cash convertible note remeasurement
Risk Factors
- No full-year guidance provided until Q2 — uncertainty on growth sustainability
- Operating expenses growing 79% YoY outpacing gross profit growth of 126%
- Pre-revenue profitability; net loss widening despite revenue growth
- Convertible note remeasurement losses may recur if fair value changes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.39 (−10.83%) |
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.39 (−10.83%) |
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.39 (+10.83%) |
Oct 5, 2026 21d ago | Press Release | $32.26 | awaiting T+60 | — | $30.39 (−5.80%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $30.39 (−7.35%) |
Sep 1, 2026 7w ago | 8-K | $30.49 | awaiting T+60 | — | $30.39 (−0.33%) |
Aug 10, 2026 11w ago | 8-K | $36.57 | awaiting T+60 | — | $30.39 (−16.90%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $30.39 (+10.91%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $30.39 (+6.93%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $30.39 (+26.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers